1
|
Métivier C, Le Saëc P, Gaschet J, Chauvet C, Marionneau-Lambot S, Hofgaard PO, Bogen B, Pineau J, Le Bris N, Tripier R, Alliot C, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L. Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma. Pharmaceutics 2023; 15:1817. [PMID: 37514004 PMCID: PMC10385603 DOI: 10.3390/pharmaceutics15071817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Revised: 06/16/2023] [Accepted: 06/16/2023] [Indexed: 07/30/2023] Open
Abstract
Although the concept of theranostics is neither new nor exclusive to nuclear medicine, it is a particularly promising approach for the future of nuclear oncology. This approach is based on the use of molecules targeting specific biomarkers in the tumour or its microenvironment, associated with optimal radionuclides which, depending on their emission properties, allow the combination of diagnosis by molecular imaging and targeted radionuclide therapy (TRT). Copper-64 has suitable decay properties (both β+ and β- decays) for PET imaging and potentially for TRT, making it both an imaging and therapy agent. We developed and evaluated a theranostic approach using a copper-64 radiolabelled anti-CD138 antibody, [64Cu]Cu-TE1PA-9E7.4 in a MOPC315.BM mouse model of multiple myeloma. PET imaging using [64Cu]Cu-TE1PA-9E7.4 allows for high-resolution PET images. Dosimetric estimation from ex vivo biodistribution data revealed acceptable delivered doses to healthy organs and tissues, and a very encouraging tumour absorbed dose for TRT applications. Therapeutic efficacy resulting in delayed tumour growth and increased survival without inducing major or irreversible toxicity has been observed with 2 doses of 35 MBq administered at a 2-week interval. Repeated injections of [64Cu]Cu-TE1PA-9E7.4 are safe and can be effective for TRT application in this syngeneic preclinical model of MM.
Collapse
Affiliation(s)
- Cassandra Métivier
- Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 44007 Nantes, France
| | - Patricia Le Saëc
- Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 44007 Nantes, France
| | - Joëlle Gaschet
- Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 44007 Nantes, France
| | - Catherine Chauvet
- Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 44007 Nantes, France
| | | | - Peter O Hofgaard
- Department of Immunology, Oslo University Hospital, 04024 Oslo, Norway
| | - Bjarne Bogen
- Department of Immunology, Oslo University Hospital, 04024 Oslo, Norway
| | - Julie Pineau
- Univ. Brest, UMR CNRS 6521 CEMCA, 6 Avenue Victor le Gorgeu, 29200 Brest, France
| | - Nathalie Le Bris
- Univ. Brest, UMR CNRS 6521 CEMCA, 6 Avenue Victor le Gorgeu, 29200 Brest, France
| | - Raphaël Tripier
- Univ. Brest, UMR CNRS 6521 CEMCA, 6 Avenue Victor le Gorgeu, 29200 Brest, France
| | - Cyrille Alliot
- Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 44007 Nantes, France
- GIP ARRONAX, 44800 Saint-Herblain, France
| | - Férid Haddad
- IMT Atlantique, Nantes Université, Subatech, 44307 Nantes, France
- GIP ARRONAX, 44800 Saint-Herblain, France
| | - Michel Chérel
- Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 44007 Nantes, France
- Nuclear Medicine Department, ICO-René Gauducheau Cancer Center, 44800 Saint-Herblain, France
| | - Nicolas Chouin
- Nantes Université, Inserm, CNRS, Université d'Angers, Oniris, CRCI2NA, 44007 Nantes, France
| | - Alain Faivre-Chauvet
- Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, CHU Nantes, 44007 Nantes, France
| | - Latifa Rbah-Vidal
- Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, 44007 Nantes, France
| |
Collapse
|